Encoded Therapeutics Presents Updated Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the 16th European Epilepsy Congress

Encoded Therapeutics Presents Updated Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the European Epilepsy Congress.

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Re…

New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer ...
quiverquant

Veru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development Plan

Veru announces sabizabulin's potential as a treatment for daraxonrasib-resistant pancreatic cancer, supported by new ...